Schrodinger had its Relative Strength (RS) Rating upgraded from 76 to 81 Wednesday.
This unique rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains typically have an 80 or higher RS Rating in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Schrodinger is now considered extended and out of buy range after clearing a 23.65 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% EPS growth in its most recent report, while sales growth came in at -17%. The next quarterly results are expected on or around Feb. 26.
The company holds the No. 23 rank among its peers in the Medical-Research Equipment/Services industry group. Champions Oncology, Veracyte and Natera are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
